Biotechnology company developing T cell engager immunotherapies for cancer.
Janux Therapeutics, Inc. is a pioneering biopharmaceutical firm specializing in the development of innovative cancer therapeutics using its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology. Founded in 2017 and based in La Jolla, California, the company is dedicated to advancing treatments aimed at addressing the complex challenges of cancer.
At the forefront of Janux Therapeutics' pipeline are its lead TRACTr product candidates, currently in preclinical or discovery stages. These candidates target critical cancer markers such as prostate-specific membrane antigen, epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2, demonstrating the company's commitment to combating various forms of cancer.
Additionally, Janux Therapeutics is developing a Tumor Activated Immunomodulator (TRACIr), a costimulatory bispecific product candidate targeting programmed death-ligand 1 (PD-L1) and CD28. This innovative approach aims to enhance the anti-tumor acttivity of T cells, potentially improving outcomes for cancer patients by bolstering immune response.
The company's EGFR-TRACTr is specifically designed to target EGFR across multiple cancer types, leveraging the efficacy of approved monoclonal antibodies. Janux Therapeutics continues to drive scientific innovation and therapeutic discovery, positioning itself as a key player in the advancement of precision oncology treatments that harness the body's immune system to fight cancer effectively.